Effects of Bu-Zhong-Yi-Qi-Tang for the Treatment of Functional Dyspepsia: a Feasibility Study Protocol

Overview

Journal Integr Med Res

Publisher Elsevier

Specialty Rehabilitation Medicine

Date 2017 Sep 28

PMID 28951846

Citations 8

Authors

Jihye Kim

Hyunho Kim

Keun Ho Kim

Affiliations

Soon will be listed here.

Abstract

Background: Bu-Zhong-Yi-Qi-Tang (BZYQT) has long been used for the treatment of severe weakness caused by general fatigue, loss of appetite, or indigestion. The aim of this feasibility study is to assess the effectiveness and safety of BZYQT for the treatment of functional dyspepsia (FD) with spleen qi deficiency.

Methods: This study will be conducted at a single center as a prospective, nonrandomized, nonblinded, single-arm feasibility study. A total of 30 participants diagnosed with FD in accordance with the Rome III criteria will be enrolled. All patients will receive BZYQT for 4 weeks. The primary outcome is the change in the Nepean Dyspepsia Index-Korean version (NDI-K) scores between the baseline and 4-week images. The secondary outcomes include the tongue coating thickness, blood parameters, and BZYQT Questionnaire score. The NDI-K score will be acquired four times, at Weeks 0 (baseline), 2 (during treatment), 4 (after treatment), and 8 (after follow-up). Written informed consent will be obtained from all study participants prior to enrollment. This study has been approved by the Institutional Review Board of Kyung Hee University Korean Medicine Hospital. This study protocol is registered with the national clinical trial registry of the World Health Organization International Clinical Trials Registry Platform. Results will be published in a journal and will be disseminated both electronically and in print.

Discussion: The results of this study may serve as a guide for researchers seeking to effectively evaluate the effects of BZYQT.

Trial Registration No: KCT0002114 (date of registration: October 21, 2016).

Citing Articles

Clinical efficacy and safety evaluation of Buzhongyiqi pills on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial.

Jianan Q, Yan X, Hongyi H, Aiguang Z J Tradit Chin Med. 2024; 44(6):1254-1267.

PMID: 39617711 PMC: 11589555. DOI: 10.19852/j.cnki.jtcm.20240806.005.

Bojungikki-Tang Augments Pembrolizumab Efficacy in Human PBMC-Injected H460 Tumor-Bearing Mice.

Na S, Yi J, Yeo H, Park S, Jeong M, Chun J Life (Basel). 2024; 14(10).

PMID: 39459546 PMC: 11508561. DOI: 10.3390/life14101246.

Medicinal plants and natural products for treating overactive bladder.

Chen H, Man Hoi M, Lee S Chin Med. 2024; 19(1):56.

PMID: 38532487 PMC: 10967063. DOI: 10.1186/s13020-024-00884-3.

Protective effect of thyroid and restores of ovarian function of Buzhong Yiqi granule on experimental autoimmune thyroiditis in female rats.

Yuezhu W, Yuyang Z, Jiajun Q, Yuyuan L, Zhongyuan X J Tradit Chin Med. 2024; 44(2):315-323.

PMID: 38504537 PMC: 10927403. DOI: 10.19852/j.cnki.jtcm.20240203.008.

Integrating network pharmacology and experimental verification to decipher the immunomodulatory effect of Bu-Zhong-Yi-Qi-Tang against poly (I:C)-induced pulmonary inflammation.

Hu L, Yamamoto M, Chen J, Duan H, Du J, He L Front Pharmacol. 2022; 13:1015486.

PMID: 36304166 PMC: 9592993. DOI: 10.3389/fphar.2022.1015486.

References

Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

Yoon K, Park Y, Park Y, Kim M . Development and validation of a Lao Juan questionnaire. Chin J Integr Med. 2015; 21(7):500-6. DOI: 10.1007/s11655-015-2079-4. View

Lu C, Lang H, Chang F, Chen C, Luo J, Wang S . Prevalence and health/social impacts of functional dyspepsia in Taiwan: a study based on the Rome criteria questionnaire survey assisted by endoscopic exclusion among a physical check-up population. Scand J Gastroenterol. 2005; 40(4):402-11. DOI: 10.1080/00365520510012190. View

Guo H, Liu M . Mechanism of traditional Chinese medicine in the treatment of allergic rhinitis. Chin Med J (Engl). 2013; 126(4):756-60. View

Monkemuller K, Malfertheiner P . Drug treatment of functional dyspepsia. World J Gastroenterol. 2006; 12(17):2694-700. PMC: 4130977. DOI: 10.3748/wjg.v12.i17.2694. View

Karamanolis G, Caenepeel P, Arts J, Tack J . Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology. 2006; 130(2):296-303. DOI: 10.1053/j.gastro.2005.10.019. View

Talley N, Verlinden M, Jones M . Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol. 1999; 94(9):2390-7. DOI: 10.1111/j.1572-0241.1999.01363.x. View

Han G, Ko S, Park J, Kim J, Yeo I, Lee H . Acupuncture for functional dyspepsia: study protocol for a two-center, randomized controlled trial. Trials. 2014; 15:89. PMC: 3994398. DOI: 10.1186/1745-6215-15-89. View

Kim J, Han G, Ko S, Nam D, Park J, Ryu B . Tongue diagnosis system for quantitative assessment of tongue coating in patients with functional dyspepsia: a clinical trial. J Ethnopharmacol. 2014; 155(1):709-13. DOI: 10.1016/j.jep.2014.06.010. View

10.

Talley N, Stanghellini V, Heading R, Koch K, Malagelada J, Tytgat G . Functional gastroduodenal disorders. Gut. 1999; 45 Suppl 2:II37-42. PMC: 1766695. DOI: 10.1136/gut.45.2008.ii37. View

11.

Anastasi J, Currie L, Kim G . Understanding diagnostic reasoning in TCM practice: tongue diagnosis. Altern Ther Health Med. 2009; 15(3):18-28. View

12.

Jung C, Nam J, Jeon Y, Kim K . Color distribution differences in the tongue in sleep disorder. Evid Based Complement Alternat Med. 2014; 2014:323645. PMC: 4020389. DOI: 10.1155/2014/323645. View

13.

Drossman D . Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016; . DOI: 10.1053/j.gastro.2016.02.032. View

14.

Yan X, Kita M, Minami M, Yamamoto T, Kuriyama H, Ohno T . Antibacterial effect of Kampo herbal formulation Hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang) on Helicobacter pylori infection in mice. Microbiol Immunol. 2002; 46(7):475-82. DOI: 10.1111/j.1348-0421.2002.tb02721.x. View

15.

Lee H, Jung H, Huh K . Current status of functional dyspepsia in Korea. Korean J Intern Med. 2014; 29(2):156-65. PMC: 3956983. DOI: 10.3904/kjim.2014.29.2.156. View

16.

Hong S, Sung I, Kim J, Lee S, Choi S, Yang C . Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of H. pylori Eradication in H. pylori-Infected Patients with Functional Dyspepsia. Gut Liver. 2011; 5(4):468-71. PMC: 3240790. DOI: 10.5009/gnl.2011.5.4.468. View

17.

Kuroiwa A, Liou S, Yan H, Eshita A, Naitoh S, Nagayama A . Effect of a traditional Japanese herbal medicine, hochu-ekki-to (Bu-Zhong-Yi-Qi Tang), on immunity in elderly persons. Int Immunopharmacol. 2004; 4(2):317-24. DOI: 10.1016/j.intimp.2003.12.004. View

18.

Zheng X, Tian J, Liu P, Xing J, Qin X . Analysis of the restorative effect of Bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model using (1)H-NMR-based metabonomics. J Ethnopharmacol. 2013; 151(2):912-20. DOI: 10.1016/j.jep.2013.12.001. View

19.

Kim J, Son J, Jang S, Nam D, Han G, Yeo I . Availability of tongue diagnosis system for assessing tongue coating thickness in patients with functional dyspepsia. Evid Based Complement Alternat Med. 2013; 2013:348272. PMC: 3789501. DOI: 10.1155/2013/348272. View

20.

Kiyohara H, Nagai T, Munakata K, Nonaka K, Hanawa T, Kim S . Stimulating effect of Japanese herbal (kampo) medicine, hochuekkito on upper respiratory mucosal immune system. Evid Based Complement Alternat Med. 2006; 3(4):459-67. PMC: 1697741. DOI: 10.1093/ecam/nel030. View